Document:

EX-10.13

 Exhibit 10.13 

PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT 

THIS PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT (as it may from time to time be amended and including all exhibits referenced herein, this
“Agreement”), dated as of October 20, 2020, is entered into by and between Supernova Partners Acquisition Company, Inc., a Delaware corporation (the “Company”), and Supernova Partners LLC, a
Delaware limited liability company (the “Purchaser”). 
 WHEREAS, the Company intends to consummate an initial
public offering of the Company’s units (the “Public Offering”), each unit consisting of one share of Class A common stock of the Company, par value $0.0001 per share (a “Share”), and one-third of one redeemable warrant, each whole warrant entitling the holder to purchase one Share at an exercise price of $11.50 per Share, as set forth in the Company’s Registration Statement on Form S-1, filed with the U.S. Securities and Exchange Commission (the “SEC”), File Number 333-249053 (the “Registration Statement”),
under the Securities Act of 1933, as amended (the “Securities Act”); and 
 WHEREAS, the Purchaser has agreed to
purchase, at a price of $1.50 per warrant, an aggregate of 6,000,000 warrants (and up to 700,000 additional warrants if the underwriters in the Public Offering exercise their over-allotment option in full) (the “Private Placement
Warrants”), each Private Placement Warrant entitling the holder to purchase one Share at an exercise price of $11.50 per Share. 

NOW THEREFORE, in consideration of the mutual promises contained in this Agreement and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties to this Agreement hereby, intending legally to be bound, agree as follows: 

AGREEMENT 

Section 1.    Authorization, Purchase and Sale; Terms of the Private Placement Warrants. 

A.    Authorization of the Private Placement Warrants. The Company has duly authorized the issuance and sale of the
Private Placement Warrants to the Purchaser. 
 B.    Purchase and Sale of the Private Placement Warrants. 

(i)    On the date of the consummation of the Public Offering or on such earlier time and date as may be mutually agreed by
the Purchaser and the Company (the “IPO Closing Date”), the Company shall issue and sell to the Purchaser, and the Purchaser shall purchase from the Company, 6,000,000 Private Placement Warrants at a price of $1.50 per
warrant for an aggregate purchase price of $9,000,000 (the “Purchase Price”). The Purchaser shall pay, at least one (1) business day prior to the IPO Closing Date, the Purchase Price by wire transfer of immediately
available funds, consisting of (i) $7,000,000 to the trust account, at a financial institution to be chosen by the Company, maintained by Continental Stock Transfer & Trust Company, acting as trustee, in accordance with the Company’s
wiring instructions (the “Trust Account”), and (ii) $2,000,000 to, or on behalf of, the Company in accordance with the 

 
Company’s wiring instructions. On the IPO Closing Date, subject to receipt of funds pursuant to the immediately prior sentence, the Company, at its option, shall deliver a certificate
evidencing the Private Placement Warrants purchased on such date duly registered in the Purchaser’s name to the Purchaser or effect such delivery in book-entry form. 

(ii)    On the date of the consummation of the closing of any over-allotment option, in connection with the Public
Offering or on such earlier time and date as may be mutually agreed by the Purchaser and the Company (an “Over-allotment Closing Date,” and each Over-allotment Closing Date (if any) and the IPO Closing Date, a
“Closing Date”), the Company shall issue and sell to the Purchaser, and the Purchaser shall purchase from the Company, up to 700,000 Private Placement Warrants (or, to the extent the over-allotment option is not exercised in
full, a lesser number of Private Placement Warrants in proportion to the portion of the over-allotment option that is then exercised) at a price of $1.50 per warrant for an aggregate purchase price of up to $1,050,000 (if the over-allotment option
is exercised in full) (the “Over-allotment Purchase Price”). The Purchaser shall pay the Over-allotment Purchase Price in accordance with the Company’s wire instruction by wire transfer of immediately available
funds to the Company or the Trust Account (as set forth in the wire instructions), at least one (1) business day prior to the Over-allotment Closing Date. On each Over-allotment Closing Date, subject to receipt of funds pursuant to the
immediately prior sentence, the Company shall, at its option, deliver a certificate evidencing the Private Placement Warrants purchased on such Closing Date duly registered in the Purchaser’s name to the Purchaser or effect such delivery in
book-entry form. 
 C.    Terms of the Private Placement Warrants. 

(i)    Each Private Placement Warrant shall have the terms set forth in a Warrant Agreement to be entered into by the
Company and a warrant agent in connection with the Public Offering (the “Warrant Agreement”). 

(ii)    On or prior to the IPO Closing Date, the Company and the Purchaser shall enter into a registration rights
agreement (the “Registration Rights Agreement”) pursuant to which the Company will grant certain registration rights to the Purchaser relating to the Private Placement Warrants and the Shares underlying the Private Placement
Warrants. 
 Section 2.    Representations and Warranties of the Company. 

As a material inducement to the Purchaser to enter into this Agreement and purchase the Private Placement Warrants, the Company hereby
represents and warrants to the Purchaser (which representations and warranties shall survive each Closing Date) that: 

A.    Incorporation and Corporate Power. The Company is a corporation duly incorporated, validly existing and
in good standing under the laws of the State of Delaware and is qualified to do business in every jurisdiction in which the failure to so qualify would reasonably be expected to have a material adverse effect on the financial condition, operating
results or assets of the Company. The Company possesses all requisite corporate power and authority necessary to carry out the transactions contemplated by this Agreement and the Warrant Agreement. 

  
 2 

 B.    Authorization; No Breach. 

(i)    The execution, delivery and performance of this Agreement and the Private Placement Warrants have been duly
authorized by the Company as of each Closing Date. This Agreement constitutes the valid and binding obligation of the Company, enforceable in accordance with its terms, subject to bankruptcy, insolvency, fraudulent conveyance, reorganization,
moratorium and other laws of general applicability relating to or affecting creditors’ rights and to general equitable principles (whether considered in a proceeding in equity or law). Upon issuance in accordance with, and payment pursuant
to, the terms of the Warrant Agreement and this Agreement, the Private Placement Warrants will constitute valid and binding obligations of the Company, enforceable in accordance with their terms as of the applicable Closing Date. 

(ii)    The execution and delivery by the Company of this Agreement and the Private Placement Warrants, the issuance and
sale of the Private Placement Warrants, the issuance of the Shares upon exercise of the Private Placement Warrants and the fulfillment of and compliance with the respective terms hereof and thereof by the Company, do not and will not as of each
Closing Date (a) conflict with or result in a breach of the terms, conditions or provisions of, (b) constitute a default under, (c) result in the creation of any lien, security interest, charge or encumbrance upon the Company’s
capital stock or assets under, (d) result in a violation of, or (e) require any authorization, consent, approval, exemption or other action by or notice or declaration to, or filing with, any court or administrative or governmental body or
agency pursuant to the certificate of incorporation or bylaws of the Company (in effect on the date hereof or as may be amended prior to the applicable Closing Date) or any material law, statute, rule or regulation to which the Company is subject,
or any agreement, order, judgment or decree to which the Company is subject, except for any filings required after the date hereof under federal or state securities laws. 

C.    Title to Securities. Upon issuance in accordance with, and payment pursuant to, the terms hereof and the
Warrant Agreement, the Shares issuable upon exercise of the Private Placement Warrants will be duly and validly issued, fully paid and nonassessable. On the date of issuance of the Private Placement Warrants, the shares issuable upon exercise
of the Private Placement Warrants shall have been reserved for issuance. Upon issuance in accordance with, and payment pursuant to, the terms hereof and the Warrant Agreement, the Purchaser will have good title to the Private Placement Warrants
purchased by it and the Shares issuable upon exercise of such Private Placement Warrants, free and clear of all liens, claims and encumbrances of any kind, other than (i) transfer restrictions hereunder and under the other agreements
contemplated hereby, (ii) transfer restrictions under federal and state securities laws, and (iii) liens, claims or encumbrances imposed due to the actions of the Purchaser. 

D.    Governmental Consents. No permit, consent, approval or authorization of, or declaration to or filing
with, any governmental authority is required in connection with the execution, delivery and performance by the Company of this Agreement or the consummation by the Company of any other transactions contemplated hereby, except for applicable
requirements of the Securities Act. 

  
 3 

 Section 3.    Representations and Warranties of the Purchaser.

 As a material inducement to the Company to enter into this Agreement and issue and sell the Private Placement Warrants to the
Purchaser, the Purchaser hereby represents and warrants to the Company (which representations and warranties shall survive each Closing Date) that: 

A.    Organization and Requisite Authority. The Purchaser possesses all requisite power and authority
necessary to carry out the transactions contemplated by this Agreement. 
 B.    Authorization; No Breach. 

(i)    This Agreement constitutes a valid and binding obligation of the Purchaser, enforceable in accordance with its
terms, subject to bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other laws of general applicability relating to or affecting creditors’ rights and to general equitable principles (whether considered in a
proceeding in equity or law). 
 (ii)    The execution and delivery by the Purchaser of this Agreement and the
fulfillment of and compliance with the terms hereof by the Purchaser does not and shall not as of each Closing Date (a) conflict with or result in a breach by the Purchaser of the terms, conditions or provisions of, (b) constitute a
default under, (c) result in the creation of any lien, security interest, charge or encumbrance upon the Purchaser’s equity or assets under, (d) result in a violation of, or (e) require any authorization, consent, approval,
exemption or other action by or notice or declaration to, or filing with, any court or administrative or governmental body or agency pursuant to the Purchaser’s organizational documents (in effect on the date hereof or as may be amended prior
to the applicable Closing Date), or any material law, statute, rule or regulation to which the Purchaser is subject, or any agreement, instrument, order, judgment or decree to which the Purchaser is subject, except for any filings required after the
date hereof under federal or state securities laws. 
 C.    Investment Representations. 

(i)    The Purchaser is acquiring the Private Placement Warrants and, upon exercise of the Private Placement Warrants, the
Shares issuable upon such exercise (collectively, the “Securities”) for its own account, for investment purposes only and not with a view towards, or for resale in connection with, any public sale or distribution thereof.

 (ii)    The Purchaser understands that the Securities are being offered and will be sold to it in reliance on
specific exemptions from the registration requirements of the United States federal and state securities laws and that the Company is relying upon the truth and accuracy of, and the Purchaser’s compliance with, the representations and
warranties of the Purchaser set forth herein in order to determine the availability of such exemptions and the eligibility of the Purchaser to acquire such Securities. 

(iii)    The Purchaser did not decide to enter into this Agreement as a result of any general solicitation or general
advertising within the meaning of Rule 502(c) under the Securities Act. 

  
 4 

 (iv)    The Purchaser understands that no United States federal or state
agency or any other government or governmental agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment in the Securities by the Purchaser nor have such authorities passed upon
or endorsed the merits of the offering of the Securities. 
 (v)    The Purchaser understands that: (a) the
Securities have not been and are not being registered under the Securities Act or any state securities laws, and may not be offered for sale, sold, assigned or transferred unless (i) subsequently registered thereunder or (ii) sold in
reliance on an exemption therefrom; (b) except as specifically set forth in the Registration Rights Agreement, neither the Company nor any other person is under any obligation to register the Securities under the Securities Act or any state
securities laws or to comply with the terms and conditions of any exemption thereunder; and (c) Rule 144 adopted pursuant to the Securities Act will not be available for resale transactions of Securities prior to a Business Combination and may
not be available for resale transactions of Securities after a Business Combination. 
 (vi)    The Purchaser has such
knowledge and experience in financial and business matters, knowledge of the high degree of risk associated with investments in the securities of companies in the development stage such as the Company, is capable of evaluating the merits and risks
of an investment in the Securities and is able to bear the economic risk of an investment in the Securities in the amount contemplated hereunder for an indefinite period of time. The Purchaser has adequate means of providing for its current
financial needs and contingencies and will have no current or anticipated future needs for liquidity which would be jeopardized by the investment in the Securities. The Purchaser can afford a complete loss of its investments in the Securities.

 (vii)    The Purchaser acknowledges and agrees that the Private Placement Warrants will bear a legend substantially
in the form set forth in the Warrant Agreement. 
 (viii)    The Purchaser is an “accredited investor” as such
term is defined in Rule 501(a)(3) of Regulation D under the Securities Act and the Purchaser has not experienced a disqualifying event as enumerated pursuant to Rule 506(d) of Regulation D under the Securities Act. 

Section 4.    Conditions of the Purchaser’s Obligations. 

The obligations of the Purchaser to purchase and pay for the Private Placement Warrants are subject to the fulfillment, on or before each
Closing Date, of each of the following conditions: 
 A.    Representations and Warranties. The
representations and warranties of the Company contained in Section 2 shall be true and correct at and as of such Closing Date as though then made. 

B.    Performance. The Company shall have performed and complied with all agreements, obligations and
conditions contained in this Agreement that are required to be performed or complied with by it on or before such Closing Date. 

  
 5 

 C.    No Injunction. No litigation, statute, rule,
regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority over the
matters contemplated hereby, which prohibits the consummation of any of the transactions contemplated by this Agreement or the Warrant Agreement. 

D.    Warrant Agreement. The Company shall have entered into the Warrant Agreement on terms satisfactory to
the Purchaser. 
 Section 5.    Conditions of the Company’s Obligations. 

The obligations of the Company to the Purchaser under this Agreement are subject to the fulfillment, on or before each Closing Date, of each of
the following conditions: 
 A.    Representations and Warranties. The representations and warranties of the
Purchaser contained in Section 3 shall be true and correct at and as of such Closing Date as though then made. 

B.    Performance. The Purchaser shall have performed and complied with all agreements, obligations and
conditions contained in this Agreement that are required to be performed or complied with by the Purchaser on or before such Closing Date. 

C.    Corporate Consents. The Company shall have obtained the consent of its Board of Directors authorizing
the execution, delivery and performance of this Agreement and the Warrant Agreement and the issuance and sale of the Private Placement Warrants hereunder. 

D.    No Injunction. No litigation, statute, rule, regulation, executive order, decree, ruling or injunction
shall have been enacted, entered, promulgated or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority over the matters contemplated hereby, which prohibits the
consummation of any of the transactions contemplated by this Agreement or the Warrant Agreement. 
 E.    Warrant
Agreement. The Company shall have entered into the Warrant Agreement. 
 Section 6.    Definitions.

 Terms used but not otherwise defined in this Agreement shall have the meaning assigned to such terms in the Registration Statement.

 Section 7.    Miscellaneous. 

A.    Successors and Assigns. Except as otherwise expressly provided herein, all covenants and agreements
contained in this Agreement by or on behalf of any of the parties hereto shall bind and inure to the benefit of the respective successors of the parties hereto whether so expressed or not. Notwithstanding the foregoing or anything to the
contrary herein, the parties may not assign this Agreement, other than assignments by the Purchaser to affiliates thereof (including, without limitation one or more of its members). 

  
 6 

 B.    Severability. Whenever possible, each provision of
this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the
extent of such prohibition or invalidity, without invalidating the remainder of this Agreement. 

C.    Counterparts. This Agreement may be executed simultaneously in two or more counterparts, none of which
need contain the signatures of more than one party, but all such counterparts taken together shall constitute one and the same agreement. Signatures to this Agreement transmitted via facsimile or e-mail
shall be valid and effective to bind the party so signing. 
 D.    Descriptive Headings;
Interpretation. The descriptive headings of this Agreement are inserted for convenience only and do not constitute a substantive part of this Agreement. The use of the word “including” in this Agreement shall be by way of
example rather than by limitation. 
 E.    Governing Law. This Agreement shall be deemed to be a contract
made under the laws of the State of New York and for all purposes shall be construed in accordance with the internal laws of the State of New York, without giving effect to conflicts of law principles that would result in the application of the laws
of another jurisdiction. 
 F.    Amendments. This Agreement may not be amended, modified or waived as to
any particular provision, except by a written instrument executed by the parties hereto. 
 [Signature page follows] 

  
 7 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement. 

 

			
	COMPANY:
	
	SUPERNOVA PARTNERS ACQUISITION COMPANY, INC.
		
	By:	 	 /s/ Michael Clifton

	Name:	 	Michael Clifton
	Title:	 	Chief Financial Officer
	
	PURCHASER:
	SUPERNOVA PARTNERS LLC
		
	By:	 	 /s/ Michael Clifton

	Name:	 	Michael Clifton
	Title:	 	Chief Financial Officer

  
 [Signature Page to
Private Placement Warrants Agreement]Exhibit 4.2

 

Execution Version

 

Vallon
Pharmaceuticals, Inc.

 

CONVERTIBLE
PROMISSORY NOTE PURCHASE AGREEMENT

 

This
Convertible Promissory Note Purchase Agreement (the “Agreement”) is made as of April 11,
2019 (the “Effective Date”) by and among Vallon Pharmaceuticals, Inc.,
a Delaware corporation (the “Company”), and the persons and entities named on the Schedule of
Purchasers attached hereto (individually, a “Purchaser” and collectively, the “Purchasers”).

 

Recital

 

To provide the Company
with additional resources to conduct its business, the Purchasers are willing to loan to the Company in one or more disbursements
up to an aggregate amount of $1,150,000, subject to the conditions specified herein.

 

Agreement

 

Now,
Therefore, in consideration of the foregoing, and the representations, warranties, covenants and conditions set forth
below, the Company and each Purchaser, intending to be legally bound, hereby agree as follows:

 

		1.	Amount
                                         and Terms of the Loan

 

1.1          The
Loan. Subject to the terms of this Agreement, each Purchaser agrees to lend to the Company
at the Closing (as hereinafter defined) the amount set forth opposite such Purchaser’s name on the Schedule of Purchasers
attached to this Agreement (each, a “Loan Amount”) against the issuance and delivery by the Company
of a convertible promissory note for such amount, in substantially the form attached hereto as Exhibit A
(each, a “Note” and collectively, the “Notes”).

 

		2.	Closing
                                         and Delivery

 

2.1          Closing.
The closing of the sale and purchase of the Notes (the “Closing”)
shall be held on the Effective Date, or at such other time as the Company and Purchasers may mutually agree (such date is hereinafter
referred to as the “Closing Date”).

 

2.2          Subsequent
Sales of Notes. At any time on or before the ninetieth (90th) day following the Closing,
the Company may sell Notes representing up to the balance of the authorized principal amount not sold at the Closing (the “Additional
Purchasers”). All such sales made at any additional closings (each an “Additional Closing”)
shall be made on the terms and conditions set forth in this Agreement and (i)  the representations and warranties of the
Company set forth in Section 3 hereof shall speak as of the Closing and the Company shall have no obligation to update any
disclosure related thereto, and (ii) the representations and warranties of the Additional Purchasers in Section 4 hereof
shall speak as of such Additional Closing. This Agreement, including without limitation, the Schedule of Purchasers, may be amended
by the Company without the consent of Purchasers to include any Additional Purchasers upon the execution by such Additional Purchasers
of a counterpart signature page hereto. Any Notes sold pursuant to this Section 2.2 shall be deemed to be “Notes,”
for all purposes under this Agreement and any Additional Purchasers thereof shall be deemed to be “Purchasers” for
all purposes under this Agreement.

 

    1 

     

    

 

Execution Version

 

2.3          Delivery.
At the Closing and each Additional Closing (i) each Purchaser shall deliver to the
Company a check or wire transfer funds in the amount of such Purchaser’s Loan Amount; and (ii) the Company shall issue
and deliver to each Purchaser a Note in favor of such Purchaser payable in the principal amount of such Purchaser’s Loan
Amount.

 

		3.	Representations,
                                         Warranties the Company

 

The Company hereby
represents and warrants to each Purchaser as of the Closing as follows:

 

3.1          Organization,
Good Standing and Qualification. The Company is a corporation duly organized, validly
existing and in good standing under the laws of the State of Delaware. The Company has the requisite corporate power to own and
operate its properties and assets and to carry on its business as now conducted and as proposed to be conducted. The Company is
duly qualified and is authorized to do business and is in good standing as a foreign corporation in all jurisdictions in which
the nature of its activities and of its properties (both owned and leased) makes such qualification necessary, except for those
jurisdictions in which failure to do so would not have a material adverse effect on the Company or its business.

 

3.2          Corporate
Power. The Company has all requisite corporate power to execute and deliver this Agreement,
to issue each Note (collectively, the “Loan Documents”) and to carry out and perform its obligations
under the terms of the Loan Documents.

 

3.3          Authorization.
All corporate action on the part of the Company, its directors and its stockholders necessary
for the authorization of the Loan Documents and the execution, delivery and performance of all obligations of the Company under
the Loan Documents, including the issuance and delivery of the Notes and the reservation of the equity securities issuable upon
conversion of the Notes (collectively, the “Conversion Securities”) has been taken or will be taken
prior to the issuance of such Conversion Securities. The Loan Documents, when executed and delivered by the Company, shall constitute
valid and binding obligations of the Company enforceable in accordance with their terms, subject to laws of general application
relating to bankruptcy, insolvency, the relief of debtors and, with respect to rights to indemnity, subject to federal and state
securities laws. The Conversion Securities, when issued in compliance with the provisions of the Loan Documents will be validly
issued, fully paid and nonassessable and free of any liens or encumbrances and issued in compliance with all applicable federal
and securities laws.

 

3.4          Governmental
Consents. All consents, approvals, orders, or authorizations of, or registrations, qualifications,
designations, declarations, or filings with, any governmental authority, required on the part of the Company in connection with
the valid execution and delivery of this Agreement, the offer, sale or issuance of the Notes and the Conversion Securities issuable
upon conversion of the Notes or the consummation of any other transaction contemplated hereby shall have been obtained and will
be effective at such time as required by such governmental authority.

 

    2 

     

    

 

Execution Version

 

3.5          Compliance
with Laws. To its knowledge, the Company is not in violation of any applicable statute,
rule, regulation, order or restriction of any domestic or foreign government or any instrumentality or agency thereof in respect
of the conduct of its business or the ownership of its properties, which violation would materially and adversely affect the business,
assets, liabilities, financial condition or operations of the Company.

 

3.6          Compliance
with Other Instruments. The Company is not in violation or default of any term of its
certificate of incorporation or bylaws, or of any provision of any mortgage, indenture or contract to which it is a party and
by which it is bound or of any judgment, decree, order or writ, other than such violations that would not individually or in the
aggregate have a material adverse effect on the Company. The execution, delivery and performance of the Loan Documents, and the
consummation of the transactions contemplated by the Loan Documents will not result in any such violation or be in conflict with,
or constitute, with or without the passage of time and giving of notice, either a default under any such provision, instrument,
judgment, decree, order or writ or an event that results in the creation of any lien, charge or encumbrance upon any assets of
the Company or the suspension, revocation, impairment, forfeiture, or nonrenewal of any material permit, license, authorization
or approval applicable to the Company, its business or operations or any of its assets or properties. The sale of the Notes and
the subsequent issuance of the Conversion Securities are not and will not be subject to any preemptive rights or rights of first
refusal that have not been properly waived or complied with.

 

3.7          Offering.
Assuming the accuracy of the representations and warranties of the Purchasers contained
in Section 4 hereof, the offer, issue, and sale of the Notes and the Conversion Securities (collectively, the “Securities”)
are and will be exempt from the registration and prospectus delivery requirements of the Securities Act of 1933, as amended (the
 “Act”), and have been registered or qualified (or are exempt from registration and qualification) under
the registration, permit, or qualification requirements of all applicable state securities laws.

 

3.8          Use
of Proceeds. The Company shall use the proceeds of sale and issuance of the Notes for
the operations of its business, and not for any personal, family or household purpose.

 

		4.	Representations
                                         and Warranties of the Purchasers

 

4.1          Authorization.
Each Purchaser represents that it is authorized to consummate the transactions contemplated hereby.

 

4.2          Purchase
for Own Account. Each Purchaser represents that it is acquiring the Securities solely
for its own account and beneficial interest for investment and not for sale or with a view to distribution of the Securities or
any part thereof, has no present intention of selling (in connection with a distribution or otherwise), granting any participation
in, or otherwise distributing the same, and does not presently have reason to anticipate a change in such intention.

 

    3 

     

    

 

Execution Version

 

4.3          Information
and Sophistication. Each Purchaser hereby: (i) acknowledges that it has received
all the information it has requested from the Company and it considers necessary or appropriate for deciding whether to acquire
the Securities, (ii) represents that it has had an opportunity to ask questions and receive answers from the Company regarding
the terms and conditions of the offering of the Securities and to obtain any additional information necessary to verify the accuracy
of the information given the Purchaser and (iii) further represents that it has such knowledge and experience in financial
and business matters such that it is capable of evaluating the merits and risk of this investment. Each Purchaser has evaluated
the merits and risks of its investment in the Securities based exclusively on its own independent review and consultations with
such investment, legal, tax, accounting and other advisers as it deemed necessary.

 

4.4          Ability
to Bear Economic Risk. Each Purchaser acknowledges that investment in the Securities
involves a high degree of risk, and represents that it is able, without materially impairing its financial condition, to hold
the Securities for an indefinite period of time and to suffer a complete loss of its investment.

 

4.5          Further
Limitations on Disposition. Without in any way limiting the representations set forth
above, each Purchaser further agrees not to make any disposition of all or any portion of the Securities unless and until:

 

(a)           There
is then in effect a Registration Statement under the Act covering such proposed disposition and such disposition is made in accordance
with such Registration Statement; or

 

(b)           The
Purchaser shall have notified the Company of the proposed disposition and shall have furnished the Company with a detailed statement
of the circumstances surrounding the proposed disposition, and if reasonably requested by the Company, such Purchaser shall have
furnished the Company with an opinion of counsel, reasonably satisfactory to the Company, that such disposition will not require
registration under the Act or any applicable state securities laws, provided that no such opinion shall be required for dispositions
in compliance with Rule 144, except in unusual circumstances.

 

(c)           Notwithstanding
the provisions of paragraphs (a) and (b) above, no such registration statement or opinion of counsel shall be necessary
for a transfer by such Purchaser to a partner (or retired partner) or member (or retired member) of such Purchaser in accordance
with partnership or limited liability company interests, or transfers by gift, will or intestate succession to any spouse or lineal
descendants or ancestors, if all transferees agree in writing to be subject to the terms hereof to the same extent as if they
were Purchasers hereunder.

 

4.6          Accredited
Investor Status. Each Purchaser is an “accredited investor” as such term
is defined in Rule 501 under the Act.

 

		5.	Further
                                         Agreements

 

5.1          “Market
Stand-Off” Agreement. Each Purchaser agrees that such Purchaser shall not sell,
transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with
the same economic effect as a sale, any Conversion Securities held by such Purchaser (other than those included in the registration)
during the 180-day period following the effective date of the Company’s first firm commitment underwritten public offering
of its Common Stock registered under the Securities Act (or such longer period as the underwriters or the Company shall request
in order to facilitate compliance with FINRA Rule 2241 or NYSE Member Rule 472 or any successor or similar rule or
regulation), provided that all officers and directors of the Company are bound by and have entered into similar agreements. Each
Purchaser agrees to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriters
that are consistent with the Purchaser’s obligations under this Section 5.1 or that are necessary to give further effect
to this Section 5.1. In addition, if requested by the Company or the representative of the underwriters of Common Stock (or
other securities) of the Company, each Purchaser shall provide, within 10 days of such request, such information as may be required
by the Company or such representative in connection with the completion of any public offering of the Company’s securities
pursuant to a registration statement filed under the Act. The obligations described in this Section 5.1 shall not apply to
a registration relating solely to employee benefit plans on Form S-1 or Form S-8 or similar forms that may be promulgated
in the future, or a registration relating solely to a transaction on Form S-4 or similar forms that may be promulgated in
the future.

 

    4 

     

    

 

Execution Version

 

5.2            Further
Assurances. Each Purchaser agrees and covenants that at any time and from time to time
it will promptly execute and deliver to the Company such further instruments and documents and take such further action as the
Company may reasonably require in order to carry out the full intent and purpose of this Agreement and to comply with state or
federal securities laws or other regulatory approvals.

 

		6.	Miscellaneous

 

6.1          Binding
Agreement. The terms and conditions of this Agreement shall inure to the benefit of and
be binding upon the respective successors and assigns of the parties. Nothing in this Agreement, expressed or implied, is intended
to confer upon any third party any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except
as expressly provided in this Agreement.

 

6.2          Governing
Law. This Agreement shall be governed by and construed under the laws of the State of
Delaware as applied to agreements among Delaware residents, made and to be performed entirely within the State of Delaware, without
giving effect to conflicts of laws principles.

 

6.3          Counterparts.
This Agreement may be executed in two or more counterparts, each of which shall be deemed
an original, but all of which together shall constitute one and the same instrument.

 

6.4          Titles
and Subtitles. The titles and subtitles used in this Agreement are used for convenience
only and are not to be considered in construing or interpreting this Agreement.

 

6.5          Notices.
All notices required or permitted hereunder shall be in writing and shall be deemed effectively
given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed electronic mail or facsimile
if sent during normal business hours of the recipient, if not, then on the next business day, (c) five days after having
been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one day after deposit with a
nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications
shall be sent to the Company at the address on the signature page below, and to Purchaser at the addresses set forth on the
Schedule of Purchasers attached hereto or at such other addresses as the Company or Purchaser may designate by 10 days advance
written notice to the other parties hereto.

 

    5 

     

    

 

Execution Version

 

6.6          Modification;
Waiver. No modification or waiver of any provision of this Agreement or consent to departure
therefrom shall be effective only upon the written consent of the Company and the holders of the Notes representing a majority
of the aggregate principal amount of all Notes then outstanding (the “Requisite Holders”). Any provision
of the Notes may be amended or waived by the written consent of the Company and the Requisite Holders.

 

6.7          Expenses.
The Company and each Purchaser shall each bear its respective expenses and legal fees
incurred with respect to this Agreement and the transactions contemplated herein.

 

6.8          Delays
or Omissions. It is agreed that no delay or omission to exercise any right, power or
remedy accruing to each Purchaser, upon any breach or default of the Company under the Loan Documents shall impair any such right,
power or remedy, nor shall it be construed to be a waiver of any such breach or default, or any acquiescence therein, or of or
in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver
of any other breach or default theretofore or thereafter occurring. It is further agreed that any waiver, permit, consent or approval
of any kind or character by Purchaser of any breach or default under this Agreement, or any waiver by any Purchaser of any provisions
or conditions of this Agreement must be in writing and shall be effective only to the extent specifically set forth in writing
and that all remedies, either under this Agreement, or by law or otherwise afforded to the Purchaser, shall be cumulative and
not alternative.

 

6.9          Entire
Agreement. This Agreement and the Exhibits hereto constitute the full and entire understanding
and agreement between the parties with regard to the subjects hereof and no party shall be liable or bound to any other party
in any manner by any representations, warranties, covenants and agreements except as specifically set forth herein.

 

[signature page follows]

 

    6 

     

    

 

In
Witness Whereof, the parties have executed this Convertible Promissory Note
Purchase Agreement as of the date first written above.

 

Company:

 

Vallon
Pharmaceuticals, Inc.

 

	By:	 /s/ David Baker	 
	Name: David Baker	 
	Title: Chief Executive Officer	 

 

Address:

Two Logan Square

100 N. 18th Street

Suite 300

Philadelphia, PA 19103

 

    

     

    

 

In
Witness Whereof, the parties have executed this Convertible Promissory Note
Purchase Agreement as of the date first written above.

 

PURCHASERS:

 

SALMON Pharma GmbH

 

	By:	 /s/ Richard Ammer	 
	Name:	Richard Ammer, MD, Ph.D	 
	Title: 	General Manager	 

 

[Signature page
to Convertible Promissory Note Purchase Agreement]

 

    

     

    

 

In
Witness Whereof, the parties have executed this Convertible Promissory Note
Purchase Agreement as of the date first written above.

 

PURCHASERS:

 

	/s/ Dov Malnik	 
	Dov Malnik	 

 

[Signature
page to Convertible Promissory Note Purchase Agreement]

 

    

     

    

 

In
Witness Whereof, the parties have executed this Convertible Promissory Note
Purchase Agreement as of the date first written above.

  

PURCHASERS:

 

	/s/ Tomer Feingold	 
	Tomer Feingold	 

 

[Signature
page to Convertible Promissory Note Purchase Agreement]

 

    

     

    

 

In
Witness Whereof, the parties have executed this Convertible Promissory Note
Purchase Agreement as of the date first written above.

 

PURCHASERS:

 

Reekuz Ltd.

 

	By:	/s/ Eli Gabso	 
	Name: Eli Gabso	 
	Title:	 

 

[Signature
page to Convertible Promissory Note Purchase Agreement]

 

    

     

    

 

In
Witness Whereof, the parties have executed this Convertible Promissory Note
Purchase Agreement as of the date first written above.

 

PURCHASERS:

 

	/s/ Asaf Berman	 
	Asaf Berman	 

 

[Signature
page to Convertible Promissory Note Purchase Agreement]

 

    

     

    

 

In
Witness Whereof, the parties have executed this Convertible Promissory Note
Purchase Agreement as of the date first written above.

 

PURCHASERS:

 

Yoad Limited

 

	By: 	/s/ Mark Attard	 
	Name: Mark Attard	 
	Title: Director	 

 

[Signature
page to Convertible Promissory Note Purchase Agreement]

 

    

     

    

 

In
Witness Whereof, the parties have executed this Convertible Promissory Note
Purchase Agreement as of the date first written above.

 

PURCHASERS:

 

Nemetz Corp.

 

	By: 	/s/ Asher Rabinowitz	 
	Name: Asher Rabinowitz	 
	Title: Authorized Signatory	 

 

[Signature
page to Convertible Promissory Note Purchase Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}]]